Immunome’s Q4: Results Fall Short, But 2026 Expectations Are Key

Immunome's Q4 Earnings: A Closer Look at the Results

Immunome's latest quarterly report revealed a notable shortfall. For the fourth quarter, the company posted an earnings per share of -$0.75, falling well below the consensus estimate of -$0.60—a miss of 25%. Revenue dropped to zero, a steep decline from $2.74 million in the same period last year. While this appears to be a disappointing outcome, the key question for investors is whether this result signals a new concern or simply continues a trend the market has already anticipated.

Context is essential. Immunome has a history of negative reactions to earnings misses. In the previous quarter, a smaller earnings miss led to a 1.68% decline in share price the next day, indicating that investors have little patience for setbacks from this biotech firm. Despite ongoing losses, the Q4 loss of -$0.75 per share was actually an improvement over last year's -$1.28. The more surprising element was the complete absence of revenue, which the company attributed to a non-cash reporting period—suggesting this was more of an accounting issue than a sign of deeper operational trouble.

Ultimately, the earnings miss was significant but not disastrous. The muted stock response suggests that investors had already braced for disappointing results. The focus now shifts from past performance to what lies ahead: Immunome’s cash reserves and the key milestones that could reshape its outlook by 2026.

Key Pipeline Milestones: Looking Ahead to 2026

Investor attention has moved beyond the recent earnings miss to the pivotal events expected in 2026. The main area of uncertainty now revolves around the regulatory journey for varegacestat, Immunome’s leading drug candidate. Following encouraging results from the Phase 3 RINGSIDE trial, the company plans to submit a New Drug Application (NDA) to the FDA for varegacestat in Q2 2026. This sets a high bar for success.

The stock’s future will depend heavily on whether this NDA submission leads to regulatory approval. Such an outcome would validate Immunome’s clinical efforts and open the door to commercialization. Conversely, any delays, requests for further data, or outright rejection would be a major setback, especially given the resources already invested.

Beyond varegacestat, Immunome is broadening its pipeline. The company intends to file Investigational New Drug (IND) applications for three novel solid tumor ADCs in 2026, diversifying its portfolio and reducing reliance on a single asset. Early clinical results from the IM-1021 ADC program are expected in 2026, with initial signs of efficacy already observed. This progress supports the potential of the HC74 payload, which aims to address resistance issues seen with other ADCs.

RSI Oversold Long-Only Strategy: Backtest Summary

• Strategy Rules: Buy IMN when RSI(14) falls below 30. Sell when RSI(14) exceeds 70, after 20 trading days, or if a 10% gain or 5% loss is reached. Backtest period: 2024-03-03 to 2026-03-03.
• Key Results:
  • Total Return: 132.1%
  • Annualized Return: 83.77%
  • Maximum Drawdown: 21.79%
  • Profit-Loss Ratio: 6.6
  • Total Trades: 10
  • Winning Trades: 3
  • Losing Trades: 7
  • Win Rate: 30%
  • Average Hold: 4.2 days
  • Max Consecutive Losses: 3
  • Average Win: 74.44%
  • Average Loss: 7.22%
  • Largest Single Gain: 190.58%
  • Largest Single Loss: 13.84%

These results highlight the potential for significant gains, but also underscore the risks and volatility associated with the strategy.

In summary, the market is treating varegacestat’s outcome as a binary event. Immunome’s recent capital raise has extended its cash runway through 2028, giving the company time to pursue these critical milestones. However, the stock’s performance will be closely tied to the successful execution of its 2026 objectives. A positive NDA outcome and encouraging ADC data could close the expectation gap and unlock value, while setbacks would likely increase investor skepticism.

Financial Position: Cash Reserves and Future Outlook

Immunome’s financial health is a crucial factor as it approaches these high-stakes milestones. The company raised $460.5 million in a public offering last December, extending its cash runway into 2028. This move directly addresses concerns about ongoing losses, with analysts projecting negative earnings through 2027 before a potential turnaround in 2028. The new funds ensure that Immunome can pursue its pipeline goals without immediate risk of dilution from further fundraising.

While the market has already factored in several years of losses, the recent capital infusion buys Immunome time to achieve commercial success. The company’s strategy is to use these resources to advance its pipeline, with the varegacestat NDA submission as the next major milestone. This financial cushion allows management to focus on execution rather than short-term funding concerns.

In essence, Immunome’s risk profile is well understood: losses are expected, but the company has the cash to sustain its operations. The real question for investors is not whether Immunome can survive, but whether it can deliver on its 2026 milestones. Any delays or failures could prompt a reassessment of the timeline, but for now, the financial foundation appears robust enough to support the company’s ambitions.

Upcoming Catalysts, Risks, and Key Developments

Immunome’s investment case now centers on several upcoming events that could either narrow or widen the gap between expectations and reality. The most closely watched development is the release of topline data from the RINGSIDE trial, anticipated before year-end. This data will confirm the Phase 3 results and set the stage for the NDA submission for varegacestat in the second quarter of 2026. The market has set a high bar for this milestone, and the real test will come during the FDA’s review process. Regulatory setbacks, such as requests for additional data or delays, would directly challenge the current investment thesis.

On a more optimistic note, progress with the ADC platform offers another potential catalyst. The ongoing Phase 1 trial for IM-1021 is expected to yield initial results in 2026. Positive findings here could validate the HC74 payload and attract partnership opportunities, providing value even if varegacestat encounters obstacles.

In conclusion, the next several months will be defined by Immunome’s ability to deliver on its 2026 objectives. The company’s cash position provides the necessary runway, but the ultimate outcome will depend on the successful achievement of these key milestones. Any missteps could force a reevaluation of the timeline, but for now, Immunome’s financial base is strong enough to support its strategic goals.